MAROSTICA, ELEONORA
 Distribuzione geografica
Continente #
NA - Nord America 524
EU - Europa 327
AS - Asia 251
AF - Africa 1
Totale 1.103
Nazione #
US - Stati Uniti d'America 514
CN - Cina 237
IE - Irlanda 137
UA - Ucraina 61
FI - Finlandia 43
DE - Germania 27
SE - Svezia 20
GB - Regno Unito 15
IT - Italia 13
SG - Singapore 13
CA - Canada 6
BE - Belgio 5
MX - Messico 4
PT - Portogallo 3
FR - Francia 1
GR - Grecia 1
HK - Hong Kong 1
MU - Mauritius 1
NL - Olanda 1
Totale 1.103
Città #
Dublin 137
Chandler 120
Jacksonville 86
Nanjing 62
Beijing 42
Ann Arbor 29
Ashburn 29
Boardman 29
Wilmington 28
Nanchang 27
Jiaxing 20
Princeton 18
Dearborn 17
Hebei 17
Lawrence 16
Shenyang 16
Tianjin 16
Medford 13
Shanghai 12
Singapore 11
Houston 10
Helsinki 8
Milan 8
Brussels 5
Changsha 5
Hangzhou 5
Renton 5
Seattle 5
Toronto 5
Woodbridge 5
Morelia 4
Bobadela 3
Falls Church 3
Jinan 3
Kunming 3
Lanzhou 3
Los Angeles 3
Ningbo 3
Dallas 2
Norwalk 2
Pavia 2
Washington 2
Dolo 1
Groningen 1
Hefei 1
Newton 1
Piscataway 1
Redwood City 1
San Francisco 1
Santa Clara 1
Surrey 1
Tappahannock 1
Vicenza 1
Xian 1
Totale 851
Nome #
First-order longitudinal population model of FEV1 data: single-trial modeling and meta-analysis 90
Continuous-time Markov modelling of flexible-dose depression trials 80
Population Pharmacokinetic Model of Ibrutinib, a BTK Inhibitor for the Treatment of B-cell malignancies 72
Integration of response, tolerability and dropout in flexible-dose trials: a case study in depression 69
A state-space approach to disease and dropout modelling in Phase II clinical trials 68
Population state-space modelling of patient responses in antidepressant studies 67
Second order Markov modelling of HAMD responses in depression trials 67
Second-order indirect response modelling of complex biomarker dynamics 65
A PCA approach to population analysis: with application to a Phase II depression trial 64
PCA-based modelling in antidepressant trials: a pre-mechanistic approach 60
Disease and dropout modelling in depression trials: a state-space approach 57
Joint Modeling of Efficacy, Dropout, and Tolerability in Flexible-Dose Trials: A Case Study in Depression 57
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies 55
The GHRH+arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences 52
Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response 50
Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in Prader-Willi adults and obese controls 48
A new, second-order indirect model of depression time course 45
Population modelling of patient responses in antidepressant studies: A stochastic approach 42
Totale 1.108
Categoria #
all - tutte 4.157
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.157


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020117 0 0 0 13 2 13 0 28 19 33 8 1
2020/2021125 17 12 5 14 0 15 2 17 3 20 16 4
2021/202279 3 1 5 3 3 3 2 5 8 1 10 35
2022/2023332 25 34 5 26 26 32 0 14 157 5 7 1
2023/2024107 17 20 2 15 5 18 4 12 0 7 5 2
2024/202535 7 25 3 0 0 0 0 0 0 0 0 0
Totale 1.108